Dekavil (F8IL10) is a fully-human anti-inflammatory product consisting of the human anti-EDA antibody F8, fused to the human cytokine, interleukin-10 (IL10).

Dekavil has demonstrated an impressive ability to selectively localize to arthritic sites in vivo, potently inhibiting arthritic progression. Dekavil is expected to be superior to non-conjugated recombinant IL10, a biopharmaceutical which has extensively been tested in phase II clinical trials in chronic inflammation and which has shown efficacy for the treatment of rheumatoid arthritis.

Phase II clinical studies in Rheumatoid Arthritis with Dekavil in combination with methotrexate have been performed by Philogen, while Pfizer has performed phase II studies with Dekavil in Inflammatory Bowel Disease (IBD).


EULAR conferences 2013, 2014, 2015
Doll et al., (2013) Arthritis Res Ther, 15, R13826, 2344-52
Schwager et al., (2011) Human Reprod, 26, 2344-52
Schwager et al., (2009) Arthritis Res Ther, 11, R142
Trachsel et al., (2007) Arthritis Res Ther, 9, R9
Trachsel et al., (2007) J Invest Dermatol, 127, 881-6


By continuing to browse or by closing this window, you accept the use of cookies.

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. By closing this banner or continuing to browse, you agree to the use of cookies.

I Accept Cookie Policy